The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Jul 13, 2026
Snapshot (as of Jul 13, 2026): Takeda Pharmaceutical Company Limited (TKPHF) pays a $200.00 annual dividend ($16.67 monthly), yielding 3.76% at $34.70/share. Next ex-dividend date 2027-03-30. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 3.76%
Annual Dividend: $200.00 per share
Payout Ratio: 162.7% (based on depressed trailing earnings — see safety analysis below)
Ex-Dividend Date: 2027-03-30
Dividend Frequency: monthly
Sector: Healthcare
Years of Dividend History: 14
Takeda Pharmaceutical Company Limited dividend reflects the income profile of one of the world's oldest biopharmaceutical companies, founded in 1781 and operating across oncology, gastroenterology, rare diseases, and plasma-derived therapies. The current yield stands at 3.76%, with a trailing annual dividend rate of $200.00 per share paid monthly. The last dividend amount was $0.6280, with the next ex-dividend date set for March 30, 2027. A beta of 0.088 points to very low price volatility, which appeals to income-focused investors who prioritize capital stability alongside yield.
Takeda Pharmaceutical Company Limited pays out 162.7% of earnings as dividends, a payout ratio classified as high (above 75%). That figure means the company is paying out more than it earns, which raises questions about Takeda Pharmaceutical Company Limited dividend safety over time, even given its broad portfolio of specialty products like Entyvio and Takhzyro serving areas of recurring medical need. The most significant data-supported pressure point is the payout ratio itself: at 162.7%, any sustained earnings shortfall leaves little room to maintain the current payment level without drawing on other resources.
Takeda Pharmaceutical Company Limited dividend history shows a CAGR of 1.4% per year from 2014 to 2025. Per-share payments moved from $1.71 to $1.9938 over that window (with 2026 a partial year and not included in the CAGR calculation). The largest annual increase in the window was 53.5% in 2025, but the history also contains at least one year-over-year decline exceeding 5%, so growth has not been linear. At 1.4% annually, dividend growth is slow, and that limits the income upside for investors counting on rising payments.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +13.7% | $1.36 (2022) | $1.99 (2025) |
| 5-Year | +3.4% | $1.69 (2020) | $1.99 (2025) |
| 10-Year | +2.9% | $1.50 (2015) | $1.99 (2025) |
TKPHF stock fits income-focused investors who want low price volatility and a moderate yield from a global biopharmaceutical business with deep roots in specialty therapeutics. The current yield of 3.76% falls within the moderate (2-4%) range and sits below the 5-year average of 3.99%, meaning today's entry yield is slightly below what the stock has historically offered. The trade-off is clear: a payout ratio of 162.7% means the dividend is not covered by current earnings, and a 1.4% annual growth rate over 11 years offers little inflation protection. What an investor gets is low market sensitivity and a monthly income stream; what they accept is a structurally stretched payout and minimal dividend growth.
| Payment Date | Amount per Share |
|---|---|
| 2027-03-30 | $0.6280 |
| 2026-09-29 | $0.6280 |
| 2026-03-31 | $0.6286 |
| 2025-09-30 | $0.6758 |
| 2025-09-29 | $0.6690 |
| 2025-03-28 | $0.6490 |
| 2024-09-27 | $0.6770 |
| 2024-03-28 | $0.6220 |
| 2023-09-28 | $0.6290 |
| 2023-03-30 | $0.6780 |
| Year | Total Dividends |
|---|---|
| 2027 | $0.6280 |
| 2026 | $1.2566 |
| 2025 | $1.9938 |
| 2024 | $1.2990 |
| 2023 | $1.3070 |
Project income from TKPHF with the TKPHF dividend calculator or track your full portfolio with the dividend tracker.